Across TCGA pan-cancer cohorts, MIAT Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MIAT data layer compared with 25 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher MIAT Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIAT expression acts as an unfavorable survival marker.

SARC and ESCA are the cancer types where MIAT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: MIAT tumor-vs-normal RNA expression · all MIAT data types